MedPath

Dexamethasone Tolerability in the Treatment of Acute Asthma in Children

Not Applicable
Completed
Conditions
Asthma
Interventions
Drug: Ora Sweet
Registration Number
NCT00973687
Lead Sponsor
IWK Health Centre
Brief Summary

The purpose of this study is to assess whether smaller volumes of oral dexamethasone result in better tolerability, specifically less vomiting, in pediatric patients during an acute asthma exacerbation.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
430
Inclusion Criteria
  • acute asthma exacerbation
  • requiring oral systemic corticosteroids for management
Exclusion Criteria
  • preference for pills over liquid formulation
  • history of Nissen fundoplication surgery
  • needed immediate airway intervention
  • require oral medications to be given via a G or J tube
  • if patient care would be compromised
  • enrolled in the study on a previous visit.

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
10 mg/mL Unsweetened FormulationDexamethasoneno prior vomiting
1 mg/mL Ora Sweet FormulationOra Sweetno prior vomiting
1 mg/mL Ora Sweet FormulationDexamethasoneno prior vomiting
10 mg/mL Unsweetened with prior vomitingDexamethasonewith prior vomiting
1 mg/mL Ora Sweet with prior vomitingOra Sweetwith prior vomiting
1 mg/mL Ora Sweet with prior vomitingDexamethasonewith prior vomiting
Primary Outcome Measures
NameTimeMethod
The primary objective of this study was to assess whether smaller volumes of oral dexamethasone resulted in better tolerability, specifically less vomiting, in pediatric patients with an acute exacerbation of asthma.During Emergency Department visit
Secondary Outcome Measures
NameTimeMethod
To evaluate asthma symptom control post emergency room visit for acute asthma exacerbation.7-14 days following emergency dept visit

Trial Locations

Locations (1)

IWK Health Centre

🇨🇦

Halifax, Nova Scotia, Canada

© Copyright 2025. All Rights Reserved by MedPath